Free Trial
→ New Banking Law #1582 Could Unlock $21 Trillion for Americans (From Brownstone Research) (Ad)tc pixel
NASDAQ:SCLX

Scilex 5/12/2023 Earnings Report

Scilex logo
$17.76 -0.47 (-2.58%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$17.78 +0.02 (+0.14%)
As of 08/29/2025 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Scilex EPS Results

Actual EPS
-$7.70
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Scilex Revenue Results

Actual Revenue
$10.58 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Scilex Announcement Details

Quarter
Date
5/12/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Scilex's next earnings date is estimated for Wednesday, November 12, 2025, based on past reporting schedules.

Conference Call Resources

Scilex Earnings Headlines

Scilex Holding Company (Nasdaq: SCLX) Announces Its Majority-Owned Subsidiary, Semnur Pharmaceuticals, Inc. (“Semnur”), and Denali Capital Acquisition Corp. Have Entered ...
August 21, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/GlobeNewswire/34296596/scilex-holding-company-nasdaq-sclx-announces-its-majority-owned-subsidiary-semnur-pharmaceuticals-inc-semnur-and-denali-capital-acquisition-corp-have-entered-into-a-purchase-agreement-with-an-investor-for-a-20-million-private/
Scilex Subsidiary Semnur Pharma Eyes $20M Private Placement Deal: More Details Inside
August 21, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/scilex-subsidiary-semnur-pharma-eyes-20m-private-placement-deal-more-details-inside/ar-AA1KX6rH
A Major Economic Change Is Happening Now
Louis Navellier is one of Wall Street’s most respected money managers — overseeing more than $7 billion and earning a reputation for fact-based analysis, not sensationalism. That’s why his latest economic warning is turning so many heads. In his new report, Louis reveals how recent policies are accelerating a massive economic shift. While headlines point to strong numbers, everyday Americans feel the squeeze as prices climb and industries are reshaped. According to Louis, this transformation could determine who falls behind — and who builds lasting wealth.tc pixel
 |  InvestorPlace (Ad)
Scilex Holding Company and Semnur Pharmaceuticals Announce $20 Million Private Placement for SP-102 Clinical Trial and Leadership Transition
August 21, 2025  |  quiverquant.comQ
Scilex Holding Company (Nasdaq: SCLX) Announces Its Majority-Owned Subsidiary, Semnur Pharmaceuticals, Inc. (“Semnur”), and Denali Capital Acquisition Corp. Have Entered into a Purchase Agreement with an Investor for a $20 Million Private Placement at $16.00 per share and Jaisim Shah, Scilex's CEO and President, Will be Dedicated to Semnur on a Full Time Basis to Rapidly Advance SP-102 to Regulato
August 21, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/21/3136968/0/en/scilex-holding-company-nasdaq-sclx-announces-its-majority-owned-subsidiary-semnur-pharmaceuticals-inc-semnur-and-denali-capital-acquisition-corp-have-entered-into-a-purchase-agreem.html
Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral ...
August 15, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SCLXW-Q/pressreleases/32439803/scilex-holding-company-presented-post-hoc-analysis-of-the-c-l-e-a-r-trial-on-clinical-meaningfulness-of-safety-and-efficacy-of-sp-102-for-the-treatment-of-lumbosacral-radicular-pain-lrp-at-the-27th-annual-meeting-of-american-society-of/
See More Scilex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scilex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scilex and other key companies, straight to your email.

About Scilex

Scilex (NASDAQ:SCLX) focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

View Scilex Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles